Treatment of wet age-related macular degeneration : Now and future
10.3760/cma.j.issn.2095-0160.2019.01.014
- VernacularTitle:创造向未来:湿性AMD治疗进展及展望
- Author:
Xiaoyan DING
1
;
Zhirong WANG
;
Limei SUN
Author Information
1. 中山大学中山眼科中心 眼科学国家重点实验室
- Keywords:
Age-related macular degeneration;
Vascular endothelial growth factor;
Monoclone antibody;
Tusion-protein
- From:
Chinese Journal of Experimental Ophthalmology
2019;37(1):63-68
- CountryChina
- Language:Chinese
-
Abstract:
Wet age-related macular degeneration (AMD),which is the leading cause of visual impairment in elderly people,significantly affects quality of life of millions worldwide.Currently,anti-VEGF is the first-line therapy for wAMD,bringing encouraging results in improving the vision.However,not all of the patients will response to this therapy,moreover,anti-VEGF may be associated with several issues,such as multiple injections,systemic adverse effects,delay or lack of response.With a deep understanding of the mechanism of wAMD,there are rapid developments of new approaches to more effective therapy.Ophthalmologists should pay attention to the advantages and disadvantages of these anti-VEGF drugs as well as the current advances of anti-VEGF drugs in order to provide better treating strategies for wAMD patients better.
